This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Müller-Tidow, C. Articles by Serve, H. Search for Related Content PubMed PubMed Citation Articles by Müller-Tidow, C. Articles by Serve, H.

Cyclin E is the Only Cyclin-dependent Kinase 2-associated Cyclin that Predicts Metastasis and Survival in Early Stage Non-Small Cell Lung Cancer¹

Department of Medicine, Hematology and Oncology [C. M-T., K. K., S. D., M. T., W. E. B., H. S.], and Department of Pathology [B. D-D.], University of Münster, 48129 Münster, Germany; Department of Visceral and Vascular Surgery, University of Cologne, 50924 Cologne, Germany [R. M., P. M. S.]; and Division of Hematology/Oncology, Cedars-Sinai Research Institute/University of California at Los Angeles School of Medicine, Los Angeles, California 90048 [G. I., H. P. K.]

Progression through G₁-S transition and S phase of the cell cycle is mediated by cyclin-dependent kinase 2 (cdk2), which interacts with several cyclins. Two of these, cyclin E and cyclin A2 (also known as cyclin A), are overexpressed in many cancers. Cyclin E2 and cyclin A1 are recently discovered cdk2-interacting cyclins that are found in malignant tumor cell lines and in acute myeloid leukemia, respectively. Expression and prognostic role of these cyclins in solid tumors is unknown. Here, we have analyzed expression and prognostic relevance of the cdk2-associated cyclins in non-small cell lung cancer (NSCLC). Fresh-frozen biopsies (n = 70) from completely resected tumors with stage I to IIIA NSCLC were studied. Gene expression was analyzed by quantitative real-time reverse transcription-PCR. Expression levels of cyclin E (P = 0.04) and cyclin A2 (P = 0.004) were significantly higher in the tumor samples than in normal controls. Cyclin A1, cyclin A2, and cyclin E2 expression levels did not have prognostic relevance for survival. The mean survival time associated with low and high levels of cyclin E was 69.4 and 47.2 months, respectively, which was statistically significant (P = 0.03). Differences in survival were particularly pronounced in stages I and II. Cyclin E was also closely associated with the development of distant metastasis (P = 0.01). Finally, we confirmed by immunohistochemistry analyses that cyclin E mRNA expression was closely associated with cyclin E protein expression. In conclusion, cyclin E is a strong independent prognostic indicator in patients with early-stage NSCLC, whereas cyclin E2, cyclin A1, and cyclin A2 do not have a prognostic role in NSCLC.

This article has been cited by other articles:

				A. H. Sikkema, S. H. Diks, W. F.A. den Dunnen, A. ter Elst, F. J.G. Scherpen, E. W. Hoving, R. Ruijtenbeek, P. J. Boender, R. de Wijn, W. A. Kamps, et al. Kinome Profiling in Pediatric Brain Tumors as a New Approach for Target Discovery Cancer Res., July 15, 2009; 69(14): 5987 - 5995. [Abstract] [Full Text] [PDF]

				M. Ozeki and J. E. Shively Differential cell fates induced by all-trans retinoic acid-treated HL-60 human leukemia cells J. Leukoc. Biol., September 1, 2008; 84(3): 769 - 779. [Abstract] [Full Text] [PDF]

				Y. Ma, S. Fiering, C. Black, X. Liu, Z. Yuan, V. A. Memoli, D. J. Robbins, H. A. Bentley, G. J. Tsongalis, E. Demidenko, et al. Transgenic cyclin E triggers dysplasia and multiple pulmonary adenocarcinomas PNAS, March 6, 2007; 104(10): 4089 - 4094. [Abstract] [Full Text] [PDF]

				C-Q Zhu, W Shih, C-H Ling, and M-S Tsao Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation. J. Clin. Pathol., August 1, 2006; 59(8): 790 - 800. [Abstract] [Full Text] [PDF]

				P. Potemski, E. Pluciennik, A. K. Bednarek, R. Kusinska, D. Jesionek-Kupnicka, G. Pasz-Walczak, C. Watala, and R. Kordek Cyclin E Expression in Operable Breast Cancer Quantified Using Real-Time RT-PCR: A Comparative Study with Immunostaining Jpn. J. Clin. Oncol., March 1, 2006; 36(3): 142 - 149. [Abstract] [Full Text] [PDF]

				S. Singhal, A. Vachani, D. Antin-Ozerkis, L. R. Kaiser, and S. M. Albelda Prognostic Implications of Cell Cycle, Apoptosis, and Angiogenesis Biomarkers in Non-Small Cell Lung Cancer: A Review Clin. Cancer Res., June 1, 2005; 11(11): 3974 - 3986. [Abstract] [Full Text] [PDF]

				C. Muller-Tidow, S. Diederichs, E. Bulk, T. Pohle, B. Steffen, J. Schwable, S. Plewka, M. Thomas, R. Metzger, P. M. Schneider, et al. Identification of Metastasis-Associated Receptor Tyrosine Kinases in Non-Small Cell Lung Cancer Cancer Res., March 1, 2005; 65(5): 1778 - 1782. [Abstract] [Full Text] [PDF]

				S. Diederichs, E. Bulk, B. Steffen, P. Ji, L. Tickenbrock, K. Lang, K. S. Zanker, R. Metzger, P. M. Schneider, V. Gerke, et al. S100 Family Members and Trypsinogens Are Predictors of Distant Metastasis and Survival in Early-Stage Non-Small Cell Lung Cancer Cancer Res., August 15, 2004; 64(16): 5564 - 5569. [Abstract] [Full Text] [PDF]

				C. Muller-Tidow, B. Steffen, T. Cauvet, L. Tickenbrock, P. Ji, S. Diederichs, B. Sargin, G. Kohler, M. Stelljes, E. Puccetti, et al. Translocation Products in Acute Myeloid Leukemia Activate the Wnt Signaling Pathway in Hematopoietic Cells Mol. Cell. Biol., April 1, 2004; 24(7): 2890 - 2904. [Abstract] [Full Text] [PDF]

				C. Muller-Tidow, J. Schwable, B. Steffen, N. Tidow, B. Brandt, K. Becker, E. Schulze-Bahr, H. Halfter, U. Vogt, R. Metzger, et al. High-Throughput Analysis of Genome-Wide Receptor Tyrosine Kinase Expression in Human Cancers Identifies Potential Novel Drug Targets Clin. Cancer Res., February 15, 2004; 10(4): 1241 - 1249. [Abstract] [Full Text] [PDF]

				U. Kronenwett, S. Huwendiek, C. Ostring, N. Portwood, U. J. Roblick, Y. Pawitan, A. Alaiya, R. Sennerstam, A. Zetterberg, and G. Auer Improved Grading of Breast Adenocarcinomas Based on Genomic Instability Cancer Res., February 1, 2004; 64(3): 904 - 909. [Abstract] [Full Text] [PDF]

				A.-I. Saez, A.-J. Saez, M.-J. Artiga, A. Perez-Rosado, F.-I. Camacho, A. Diez, J.-F. Garcia, M. Fraga, R. Bosch, S.-M. Rodriguez-Pinilla, et al. Building an Outcome Predictor Model for Diffuse Large B-Cell Lymphoma Am. J. Pathol., February 1, 2004; 164(2): 613 - 622. [Abstract] [Full Text] [PDF]

				C. Hamdouchi, H. Keyser, E. Collins, C. Jaramillo, J. E. De Diego, C. D. Spencer, J. A. Dempsey, B. D. Anderson, T. Leggett, N. B. Stamm, et al. The discovery of a new structural class of cyclin-dependent kinase inhibitors, aminoimidazo[1,2-a]pyridines Mol. Cancer Ther., January 1, 2004; 3(1): 1 - 9. [Abstract] [Full Text]

				M. D. Brundage, D. Davies, and W. J. Mackillop Prognostic Factors in Non-small Cell Lung Cancer* : A Decade of Progress Chest, September 1, 2002; 122(3): 1037 - 1057. [Abstract] [Full Text] [PDF]